Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

A Randomized, Open-label, Single-dose, Parallel-controlled Phase I Clinical Trial Comparing the Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult subjects. Eligible healthy participants will be screened and randomly assigned to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or Ozempic® injection 0.25mg abdominal subcutaneous injection will be given according to their groups. Follow-up for 5 weeks after administrtion.

Studies included a screening period (up to 2 weeks), baseline, administration (single dose), and a follow-up period (5 weeks). The duration of the study will be approximately 7 weeks for a participant.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: HDG1901; Drug: Ozempic®

• Study Type: Interventional
• Enrollment (Actual): 68
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China, 230601
      • The Second Hospital of Anhui Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Participants must meet all of the following criteria to be enrolled in the study:

1. Voluntarily participate in the trial and sign the informed consent; Willing and able, in the investigator's judgment, to comply with all experimental requirements and restrictions;
2. Healthy men and women, aged 18 to 55 years old (including);
3. Body mass index (BMI) 19.0~25.0 kg/m2 (including), weight ≥50.0 kg;
4. Physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory examination, no clinically significant abnormalities;

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded:

1. Have a history of clinically serious disease or currently have any clinically significant cardiovascular, metabolic, endocrine, kidney, liver, gastrointestinal, hematological, respiratory, cutaneous, neurological, gynecological, psychiatric or other disease;
2. A history of medullary thyroid carcinoma (MTC), multiple endocrine adenoma (MEN) 2A or 2B syndrome, or related family history; Or other malignant tumor history;
3. Subjects with a history of acute and chronic pancreatitis, symptomatic gallbladder history, pancreatic injury history and other high-risk factors that may lead to pancreatitis;
4. In the screening period, calcitonin was greater than the upper limit of normal;
5. Patients with HbA1c greater than 6.5% during the screening period;
6. Those who smoked more than 5 cigarettes per day in the 3 months before screening and those who could not smoke during the whole test period;
7. Those who have a history of alcohol abuse in the six months prior to screening, or who cannot abstain from alcohol during the test period;
8. Consume any food or drink containing caffeine, alcohol, xanthine or grapefruit (such as coffee, strong tea, chocolate, etc.) within 48 hours before check-in;
9. Known or suspected allergy to semaglutide injection or similar products and excipients;
10. Participants in clinical trials of any approved or unapproved investigational drug/device within 90 days prior to screening;
11. Pregnant and lactating female subjects;
12. Patients with difficulty in venous blood collection;
13. Those who were vaccinated within 4 weeks prior to screening or planned to be vaccinated during the trial;
14. People who donate blood or lose more than 400 mL of blood or receive blood transfusions or use blood products in the 3 months prior to screening;
15. Patients who have previously received Semaglutide injection or other GLP-1 or GLP-1/ GIP-like treatment;
16. Those who have a history of drug abuse or test positive for drug abuse screening;
17. Those who test positive for blood alcohol;
18. For any other reason, the investigator does not consider the volunteer to be suitable for participation in this clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Experimental group: Semaglutide injection, specifications: 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous abdominal injection.	Drug: HDG1901; Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
Active Comparator: Active Comparator; Control group: Ozempic ® injection, 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous injection into the abdomen.	Drug: Ozempic®; Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-inf	Area Under the Concentration-time curve from time zero to infinite time	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
AUC0-t	Area Under the Concentration-time curve from time zero to the last measurable concentration	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
Cmax	Maximum concentration of the active substance in the blood plasma of participants during the observation period	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC_%Extrap	Extrapolated Part Percentage of AUC0-inf	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
Tmax	Time of maximum concentration observed	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
t 1/2	Elimination half life	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
λz	The Volume of Distribution at Terminal Phase	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
CL	Clearance Rate	-60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration
Safety and Immunogenicity	Adverse events and positive rate of anti-drug antibodies	AEs will be collected after assigning the ICF. Immunogenicity sample will be collected at -60 minutes and 336、840 hours after administration.

Collaborators and Investigators

• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 22, 2024
• Primary Completion (Actual): November 14, 2024
• Study Completion (Actual): February 12, 2025

Study Registration Dates

• First Submitted: September 24, 2024
• First Submitted That Met QC Criteria: October 8, 2024
• First Posted (Actual): October 10, 2024

Study Record Updates

• Last Update Posted (Actual): August 1, 2025
• Last Update Submitted That Met QC Criteria: July 30, 2025
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: semaglutide; Glucagon-Like Peptide-1 Receptor Agonists
• Additional Relevant MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists; Physiological Effects of Drugs; Hypoglycemic Agents; Semaglutide
• Other Study ID Numbers: HDG1901-103

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No